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Renal cell carcinoma is an indolent disease diagnosed with distant
metastases in a significant proportion of patients. It is usually
resistant to chemotherapy; a significant improvement in treatment
could be achieved by introduction of cytokines into treatment
regimens (Atzpodien et al, 1990). The molecular mechanisms of
metastases formation are largely unknown.
Cell adhesion molecules are cell surface receptors involved in
leucocyte homing, adhesion and migration. Although these
proteins are usually membrane-bound, soluble forms exist and are
generated by shedding of the extracellular portions from the cell
surface (Rothlein et al, 1991).
Intercellular adhesion molecule-1 (ICAM-1) and vascular cell
adhesion molecule 1 (VCAM-1) belong to the immunoglobulin
superfamily and are expressed on a wide variety of cells including
endothelia, antigen-presenting cells and B-cells (Roit et al, 1996;
van den Stolpe and van der Saag, 1996). The ICAM-1-ligand,
LFA-1 (Marlinn and Springer, 1987; Roit et al, 1996), is expressed
on most leukocytes, including T-cells and NK-cells; the VCAM-1
ligand, VLA-4, is primarily expressed on lymphocytes. These
ligands belong to the integrin superfamily (Roit et al, 1996). E-
selectin (ELAM-1) is expressed on endothelium and its N-terminal
lectin domain binds to carbohydrate groups associated with a
variety of proteins of leukocyte cell surfaces, like the CD15 asso-
ciated Lewis-X carbohydrate group (Roit et al, 1996).
Prior studies have demonstrated significant differences in
expression of VLA-integrins between normal kidney tissue and
low/high grade renal cell carcinoma specimens (Anastassiou et al,
1995). Another example for a possible relevance of cell adhesion
molecule expression in the course of malignant disease is the fact
that endothelial and leucocyte expression of PECAM-1 has shown
impact on leucocyte infiltration of the tumour tissue and on patient
survival (Anastassiou et al, 1995). However, it remains unclear
whether serum levels of the soluble isoforms are of prognostic
value. To test this hypothesis in advanced renal cell carcinoma, we
examined sera from 99 patients for pretreatment serum levels of
sICAM-1, sVCAM-1 and sELAM-1.
PATIENTS AND METHODS
Patient selection and treatment
Between 1989 and 1996, 99 patients were assigned to receive
either immunotherapy or combined chemo-/immunotherapy
according to the following schedule:
Interferon-a subcutaneously, 5 MIU m–2 on day 1 of weeks 1
and 4, on days 1, 3, 5 of weeks 2 and 3; 10 MIU m–2 on days 1, 3,
5 of weeks 5–8. Interleukin-2 subcutaneously, 20 MIU m2, on days
3, 4, 5 of weeks 1 and 4, and 5 MIU m–2 on days 1, 3, 5 of weeks 
2 and 3. Additionally, for patients in the combined chemo-/
immunotherapy group, 5-fluorouracil was administered on day 1
of weeks 5–8 as a 1000 mg m–2 intravenous infusion. Concomitant
medication was given as needed to control adverse effects of
immunotherapy.
All patients had histologically (by nephrectomy) confirmed
metastatic renal cell carcinoma in progressive state and a
Karnofsky performance status of ³ 70%. Written informed consent
was obtained from each patient prior to administration of any
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study medication; response and survival were assessed according
to World Health Organization (WHO) criteria. Table 1 shows the
patient characteristics.
Sample collection and soluble cell adhesion molecule
serum level measurements
Serum samples were obtained from each patient prior to initiation
of therapy and stored at – 70°C until analysis. Soluble cell adhe-
sion molecule serum levels were determined by enzyme-linked
immunosorbent assay (ELISA) as follows: sVCAM-1, Medgenix,
Ratingen, Germany; sICAM-1 and sELAM-1, Quantikine, R&D,
Wiesbaden, Germany. All analyses were performed in duplicate,
and sera were diluted to reach a concentration within the standard
curve of the respective assay, when necessary.
As shown previously (Franzke et al, 1998), analysis of sera from
10 healthy control subjects showed mean serum values ± SEM for
sVCAM-1, sICAM-1 and sELAM-1 of 509 ng ml–1 ± 14 ng ml–1,
208 ng ml–1 ± 12 ng ml–1 and 54 ng ml–1 ± 7 ng ml–1, respectively.
Statistical analysis
The statistical end point was overall survival from treatment start.
Survival analysis and univariate risk factor analysis were
performed according to the method of Kaplan and Meier, and
multvariate risk factor analysis according to the two-proportional
Cox regression analysis with forward selection of variables.
Impact of potential risk factors on survival was calculated with
log-rank statistics. Clinical parameters and soluble cell adhesion
molecules were tested as dichotomized variables, defining the cut-
off value as the value that best discriminates between good and
poor overall survival.
RESULTS
Overall survival and univariate risk factor analysis
Median survival of all patients entered into the study was 23
months, with 35 patients being alive at last follow-up. Survival
ranged from 1 to 80+ months. As shown in Table 2, of all cell adhe-
sion molecule serum levels assayed, only sICAM-1 showed a
predictive significance, with a median survival of 27 months in
patients with pretreatment sICAM-1 serum levels below 
360 ng ml–1 as opposed to a median survival of 8 months in patients
with elevated pretreatment sICAM-1 serum levels (P = 0.0011).
In addition, the following pretreatment clinical factors could be
identified as univariate predictors of overall survival: elevated
erythrocyte sedimentation rate (ESR) (P = 0.001; median survival,
30 vs 10 months), elevated serum C-reactive protein (CRP) (P =
0.0001; median survival, 37 vs 15 months), elevated serum lactic
dehydrogenase (P = 0.0158; median survival, 25 vs 8 months) and
Table 1 Patient characteristics and risk categories according to elevated
serum levels of soluble ICAM-1
Characteristic All patients sICAM-1 sICAM-1
< 360 ng ml ³ 360 ng ml
Entered 99 87 11
Sex
Male 73 66 7
Female 26 22 4
Age (years)
Median 58 58 52
Range 32–74 32–74 40–68
Metastases
Bone 29 22 7
Brain 15 14 1
Liver 21 19 2
Lung 74 65 9
Other 52 45 7
Treatment response
Complete response 11 11 0
Partial remission 28 27 1
Stable disease 45 38 7
Progressive disease 15 12 3
Median survival (months) 23 26 8
5-Year survival (%) 22 26 0
Table 2 Pretreatment clinical factors and their prognostic significance as determined by univariate Kaplan–Meier analysis
Risk factor Categories compared P-value
Clinical features
Age < 60 vs ³ 60 years 0.1545
Sex Male vs Female 0.6317
ESR < 70 vs ³ 70 mm h–1 0.001
CRP < 8 vs ³ 8 mg ml–1 0.0001
Haemoglobin level < 10 vs ³ 10 g dl–1 0.0773
Absolute neutrophil count ≤ 6000 vs > 6000 ml–1 0.0025
Serum lactic dehydrogenase < 240 vs ³ 240 U l–1 0.0158
Time from diagnosis to first occurrence of metastases ≤ 12 vs > 12 months 0.1047
Time from first occurrence of metastases to treatment start < 10 vs ³ 10 months 0.3697
Osseous metastases Absent vs present 0.4187
Cerebral metastases Absent vs present 0.0603
Hepatic metastases Absent vs present 0.8593
Pulmonary metastases Absent vs present 0.9783
Adhesion molecules
sICAM-1 < 360 vs ³ 360 ng ml–1 0.0011
sELAM-1 < 60 vs ³ 60 ng ml–1 0.1004
sVCAM-1 < 770 vs ³ 770 ng ml–1 0.79701744 R Hoffmann et al
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elevated absolute neutrophil count (P = 0.0025; median survival,
28 vs 11 months). No predictive power could be shown for
sVCAM-1 serum level, sELAM-1 serum level, sex, age, haemo-
globin level, time from diagnosis to first occurrence of metastases,
or time from first occurrence of metastases to treatment start. Also,
the presence or absence of osseous, cerebral, hepatic, or
pulmonary metastases had no prognostic value.
Multivariate risk factor analysis
Among all pretreatment risk factors identified by univariate
analysis, a multivariate Cox regression analysis was performed to
identify statistically independent predictors of survival. Elevated
serum sICAM-1 level, ESR and serum CRP were found to be
significant and statistically independent (Table 3). Of these predic-
tors, sICAM-1 level showed a particular power to discriminate
between good risk and poor risk patients (P = 0.0092).
Comparing 5-year survival rates, patients with low (< 360 ng
ml–1) sICAM-1 levels and patients with elevated (³ 360 ng ml–1)
sICAM-1 levels reached 26% and 0%, respectively. Also, response
rates differed significantly between these two groups: all patients
achieving complete responses had low pretreatment sICAM-1
levels (Table 1).
DISCUSSION
The present study examined prognostic significance of pretreat-
ment soluble cell adhesion molecule serum levels and other clinical
laboratory parameters in unselected metastatic renal cell carcinoma
patients. Serum sICAM-1 levels, ESR and serum CRP levels could
be identified as highly significant and statistically independent
predictors of overall survival. While ESR and CRP are rather
unspecific indicators of inflammatory activity, sICAM-1 expres-
sion needs closer attention.
ICAM-1 has been reported to be aberrantly expressed on cells
from a variety of human malignancies: myeloid leukaemias (Maio
et al, 1990), B-cell lymphoproliferative disorders (Maio et al,
1990), neuroblastoma (Foreman et al, 1993), non-small-cell lung
cancer (NSCLC) (Passlick et al, 1994), prostate carcinoma (Wolff
et al, 1995) and head and neck squamous cell carcinoma (Vora et
al, 1997). While its expression on tumour cells is generally linked
to poor prognosis, in NSCLC it appears to be rather expressed by
well-differentiated and localized tumours (Passlick et al, 1994).
Particular attention has been directed to ICAM-1 expression in
malignant melanoma, where it can be demonstrated in the majority
of cases. Increased expression in metastases as compared to the
primary tumour has been demonstrated, suggesting a role in the
formation of metastases (Natali et al, 1990). Furthermore, ICAM-
1-positive primary melanomas tend to recur after surgical excision
(Natali et al, 1997). Surprisingly, these features seemed to be
unique to melanoma and could not be reproduced in a variety of
malignancies from different embryonal origins (Natali et al, 1990)
and in renal cell carcinoma (Heicapell et al, 1994).
Not only the expression of ICAM-1 on tumour cells has demon-
strated prognostic significance, but also the level of the soluble
form as measured in patients’ sera. This has been demonstrated for
acute lymphoblastic leukaemia (Hatzistilianou et al, 1997), malig-
nant melanoma (Schadendorf et al, 1996), non-Hodgkins lymph-
oma (Christiansen et al, 1996), Hodgkin’s disease (Christiansen et
al, 1995) and hepatocellular carcinoma (Shimizu et al, 1995),
amongst others.
We demonstrated the prognostic significance and independence
not only for pretreatment sICAM-1 level, but also for ESR and CRP.
Notably, elevated serum sICAM-1 by itself was capable of identi-
fying patients at highest risk, i.e. with a 5-year survival probability
of 0%. Although we could demonstrate statistical independence of
sICAM-1 levels and each of the above acute phase reactants, earlier
studies demonstrated a possible correlation between acute phase
reactants and sICAM-1 levels (Reinhardt et al, 1996) or between
ESR and serum CRP level (Ljungberg et al, 1990).
Since earlier studies have shown soluble ICAM-1 to be active in
influencing the cell-surface ICAM-1/LFA-1 interaction (Welder et
al, 1993; Meyer et al, 1995), another issue is that of a potential role
of sICAM-1 in formation of metastases and tumour progression,
leading to impaired prognosis.
It might be hypothesized that ICAM-1 on circulating tumour
cells results in attachment to the capillary endothelium via specific
ligands, which in this case still need to be defined. This attachment
of cells might ultimately lead to formation of metastases. Since the
soluble form of ICAM-1 is produced by shedding of the extra-
cellular portion of the membrane-bound form, it seems likely that
high sICAM-1 levels can be found in patients whose tumours
express large amounts of surface ICAM-1. However, in that
scenario, high sICAM-1 serum levels would occupy the endothe-
lial receptors, preventing tumour cells from adherence and metas-
tases formation. 
ICAM-1 is not only involved in cell homing and migration, 
but also in various cell-to-cell interactions with immunological
Table 3 Statistically independent risk factors identified by multivariate Cox
regression analysis
Risk factor Categories compared P-value
Serum sICAM-1 level < 360 ng ml–1 vs ³ 360 ng ml–1 0.0092
Serum C-reactive protein < 8 mg l–1 vs ³ 8 mg l–1 0.0164
Erythrocyte sedimentation rate < 70 mm 1 h–1 vs ³ 70 mm 1 h–1 0.0226
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Figure 1 Pretreatment sICAM-1 serum levels and survival in 99 patients
with metastatic renal cell carcinoma. Survival curves (Kaplan–Meier
estimate) of patients with either low (< 360 ng ml–1) or elevated (³ 360 ng ml)
pretreatment serum levels of sICAM-1. P-value was determined by log-rank
test. Tick marks represent patients for whom data were censored (n = 34 and
n = 1, for patients with low or elevated pretreatment serum sICAM-1 levels,
respectively)sICAM-1 in metastatic renal cell carcinoma 1745
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significance, such as T-cell-mediated cytotoxicity (Makgoba et al,
1998), NK-cell-mediated cytotoxicity (Chong et al, 1994), B–T-
cell interaction (Boyl et al, 1998; Amblard et al, 1994), T-cell
adhesion (Sung et al, 1992), or B-cell activation (Moy and Brian,
1992). Hence, another scenario seems possible: by binding to its
ligands on immune effector cells, like LFA-1 on T-cells, the
soluble form could effectively inhibit different anti-tumour
immune effects like effector mechanisms of cytotoxic T-cell or
NK-cells or antigen-dependent respectively T-cell-dependent B-
cell activation; this could be part of an immune escape mechanism
of tumour cells, and could possibly explain the coincidence of high
serum sICAM-1 levels and impaired prognosis. Some of these
effects have already been demonstrated in vitro (Fecondo et al,
1991; Becker et al, 1993), underlining the possibility of a specific
action of ICAM-1 in the immune escape of malignant cells.
Although further investigation is needed, this could clearly be a
target for future therapeutic trials.
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